8/11 of the Doctors Who Advised on Kisunla Approval Had Conflicts of Interest
The new monoclonal anti-amyloid Alzheimer’s drugs are a constant source of controversy among doctors, insurers, and regulators worldwide. One of this buzzy new drug class,…